SPRY4 and hypogonadotropic hypogonadism: A frequently with congenital hypogonadotropic hypogonadism-associated alteration [23,26] affecting the Raf-binding domain of Spry4 was shown to be a hyperactive inhibitor of cell proliferation and migration [27].